Lexicon Pharmaceuticals (LXRX) Shares Outstanding (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Shares Outstanding (Entity) data on file, last reported at $425.7 million in Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 16.45% year-over-year to $425.7 million in Q1 2026; TTM through Mar 2026 was $425.7 million, a 16.45% increase from a year earlier, with the FY2025 full-year figure at $365.8 million, up 0.78% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $425.7 million, up from $365.8 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for LXRX reached as high as $425.7 million in Q1 2026 and fell as low as $150.1 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $281.8 million across 5 years, with a median of $247.8 million in 2024.
• Across the five-year window, Shares Outstanding (Entity) soared 77.27% in 2024 and grew 0.76% in 2025, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $189.2 million in 2022, then climbed by 29.9% to $245.8 million in 2023, then surged by 47.69% to $363.0 million in 2024, then gained by 0.78% to $365.8 million in 2025, then gained by 16.36% to $425.7 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $425.7 million in Q1 2026, $365.8 million in Q4 2025, and $365.8 million in Q3 2025.